Medi Assist Healthcare Services Limited has appointed M/s. PricewaterhouseCoopers Services LLP as its Internal Auditors for the financial year 2026-2027. The decision was approved by the Board of Directors at their meeting held on May 09, 2026, acting on the recommendation of the Audit Committee. The appointment has been disclosed pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with the relevant SEBI Master Circular.

Appointment Details

The Board meeting commenced at 02:30 p.m. (IST) and concluded at 05:30 p.m. (IST) on May 09, 2026. The key details of the appointment, as disclosed under Regulation 30 of the SEBI Listing Regulations, are summarised below:

Profile of PricewaterhouseCoopers Services LLP

PricewaterhouseCoopers Services LLP (PwC) is among the leading professional services networks in the world. The firm operates with more than 364,000 people across 136 countries and 137 territories. PwC's service offerings span audit and assurance, tax and legal, deals, and consulting, supporting clients across a broad range of industries and geographies.

Regulatory Compliance

The intimation has been made in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. The disclosure was signed by Rashmi B V, Company Secretary & Compliance Officer (ICSI Membership No: A38729), on behalf of Medi Assist Healthcare Services Limited. The filing has also been made available on the company's website at www.mediassist.in .

Medi Assist Healthcare Services Limited has submitted its statement of deviation or variation in utilisation of funds raised through a Preferential Issue for the quarter ended March 31, 2026, in compliance with Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The statement was reviewed and approved by the company's Audit Committee and Board of Directors at their meeting held on May 09, 2026. The company confirmed that there has been no deviation or variation in the utilisation of funds from the objects stated in the explanatory statement to the notice for the Preferential Issue.

Preferential Issue: Key Details

The Preferential Issue was completed on October 10, 2025, with the company raising a total of INR 1,98,00,35,000/-. The funds were transferred from the escrow account to the company's bank account in two tranches on December 30, 2025 and December 31, 2025. CARE Ratings Limited was appointed as the Monitoring Agency to oversee the utilisation of the issue proceeds, operating under the Monitoring Agency Agreement dated September 15, 2025 and January 09, 2026.

Fund Utilisation Progress as at March 31, 2026

The issue proceeds were allocated across two primary objects. As at the end of the quarter ended March 31, 2026, Rs. 148.40 crore had been utilised towards investment in the subsidiary for debt prepayment/repayment, while the general corporate purposes allocation remained entirely unutilised. No funds were deployed during the quarter under review; the utilisation of Rs. 148.40 crore was recorded as at the beginning of the quarter, reflecting deployment in Q3FY26.

Deployment of Unutilised Proceeds

The total unutilised amount of Rs. 49.60 crore has been temporarily deployed in liquid mutual funds and a subsidiary's current account, pending utilisation as per the stated objects. The following table details the deployment of these proceeds as at the end of the quarter:

Monitoring Agency Findings

CARE Ratings Limited, in its Monitoring Agency Report for the quarter ended March 31, 2026, confirmed that all utilisation is as per the disclosures in the offer document, with no material deviation observed. The report noted that Rs. 148.40 crore was utilised in Q3FY26 as per the objects specified in the Extraordinary General Meeting (EGM) resolution dated September 04, 2025, and there was no utilisation during Q4FY26. The Monitoring Agency also confirmed no deviation from the previous monitoring agency report dated February 06, 2026. Both the investment in subsidiary for debt prepayment/repayment and the general corporate purposes objects are noted as ongoing, with a completion timeline of within 2 years as per the offer document. The CA certificate for this report was issued by M/s Dangi Jain & Company, dated April 24, 2026.